cyrilzakka/clinical-trials huggingface dataset:
Laser Therapy and Temporomandibular Disorders

TMD involves a set of multiple clinical manifestations where the pain is prevalent. Treatment ideally should be noninvasive and innocuous such as photobiomodulation


Eligibility Criteria:
Inclusion Criteria:

* Pain at TMJ area.
* Pain at masseter and temporalis muscles.
* Age ranges between 20 and 40 years old.
* Presence of full or nearly full complement of natural teeth

Exclusion Criteria:

* Patients who have radiographic evidence of degenerative conditions of TMJ.
* Patients under current dental or physical therapy that could affect TMD.
* History of recent trauma.
* The presence of systemic diseases (i.e. rheumatoid arthritis, osteoarthritis).
* Pregnant and lactating females
Type 1 Multiple Endocrine Neoplasia Cohort Study

Type 1 - Multiple Endocrine Neoplasia syndrome (MEN1,) is an autosomal dominant disorder secondary to MEN1 mutations that predisposes carriers to endocrine tumors. The MEN1 gene located on chromosome 11q13 encodes menin, a 610 amino acid protein expressed in all tissues tested. Menin is a scaffold protein which interacts with a large number of intracellular molecules. MEN1 disease may display various clinical associations The tumors mainly develop from endocrine tissues and may arise from parathyroid glands, duodeno-pancreas, pituitary gland, adrenal glands, and at a lower frequency from the bronchi and thymus. The penetrance is very progressive but ultimately high during a lifespan.

Although the syndrome was discovered in 1903 by Erdheim and properly documented in 1954 by Wermer, it was only in the 1970s that the variety of clinical presentations was acknowledged and first attempts to codify treatments were made. Most published studies deals with selected and small size populations. Thus, many aspects of the natural history of MEN1 remains unknown as well as the optimal care of patients. In addition, although advances in genetics improved the diagnosis of MEN1, there are still clinical forms whose attachment to the syndrome is difficult: atypical, paucisymptomatic, forms the negative genetic diagnosis (10%). These clinical forms need to be clarified to ensure optimum support.

This cohort relies on the Groupe d'étude des Tumeurs Endocrines (GTE) network for MEN1, created in February 1991, and brings together clinical centers in France and Belgium (n=80) as well as the four genetics laboratories in charge of MEN1 diagnosis. It aims at improving the knowledge of the MEN1mainly in describing:

* its evolution over time globally and according to the initial presentation, ( particularly accounting the risk of the occurrence of secondary MEN1 related or unrelated tumors, and death)
* the genotype-phenotype correlations and heritability of the disease
* the real life management of patients and its impact on cure and survival for each type of MEN1-related tumor
* the impact of the NEM on the patients' daily lives, their perception of the disease and their satisfaction with their care


Eligibility Criteria:
Patients with MEN1 according to the Gubbio criteria :

* Patients with a MEN1 mutation and presenting at least one of the following symptomatic or silent lesions: pHPT or pancreatic or duodenal endocrine tumor
* Pituitary tumor
* Adrenal tumor
* th-NET
* br-NET
* And gastric enterochromaffin-like tumor (ECLoma).
* Patients belonging to a known MEN1 family (at least one first-degree relative affected) and presenting at least one of the aforementioned lesions.
* Patients without positive genetic testing or a family background presenting at least two of the three major MEN1 lesions (pHPT, pancreatic, or duodenal endocrine tumor, pituitary tumor).:
Effect of Fermented Prunus Mume Vinegar on Improvement of Fatigue

The investigators conduct a randomized, double-blind, placebo-controlled study to investigate the effects of Fermented Prunus Mume Vinega on Improvement of Fatigue in adults for 8 weeks.

Previous studies have indicated that Fermented Prunus Mume Vinega may have the ability to improve fatigue. Therefore, the investigators conduct a randomized, double-blind, placebo-controlled study to investigate the effects of tFermented Prunus Mume Vinega on Improvement of Fatigue in adults; the safety of the compound are also evaluate. The Investigators examine fatigue severity scale, lactate, creatinine kinase, urinary malondialdehyde at baseline, as well as after 4 and 8 weeks of intervention. Sixty adults were administered either 600 mg of Fermented Prunus Mume Vinega or a placebo each day for 8 weeks;

Eligibility Criteria:
Inclusion Criteria:

* Those who complain of fatigue for more than 1 month
* Fatigue Severity Scale 3 points or more

Exclusion Criteria:

* chronic hepatitis B or C infection
* being treated for hypothyroidism or hyperthyroidism
* more than twice the normal upper limit of Creatinine
* Liver enzyme value is more than twice the normal upper limit
* Uncontrolled diabetes (over 160 mg / dl of fasting blood sugar)
* Uncontrolled hypertension (more than 160/100 mmHg, measured after 10 minutes of stability in subjects) or those with heart disease, such as angina or myocardial infarction
* taking medications that affect fatigue within the past 1 month (psychiatric drugs such as Chinese medicine, soy drugs, depression, beta-blockers, steroids, hormones, etc.). However, intermittent medication due to sleep disorders is excluded.
* a history of gastrointestinal resection or complain of severe gastrointestinal symptoms such as heartburn and indigestion
* already have participated in or plan to participate in another drug clinical trial
* Alcohol abusers
* pregnant, lactating or have a pregnancy plan during the clinical trial period
* allergic reactions to Fermented Prunus Mume Vinegar
* A person deemed inappropriate by the researcher for other reasons
Yoga for Chronic Low Back Pain and Its Mechanism of Action (YoMA)

This is a study to better understand how a yoga intervention helps improve symptoms in people with chronic low back pain. This study will be a 12-week intervention of about 24 participants with chronic low back pain where all individuals will receive weekly yoga classes and instructions for home practice. The purpose of this study is to collect feasibility data and to conduct preliminary analyses in preparation for a larger planned NIH study.


Eligibility Criteria:
Inclusion Criteria:

* Chronic low back pain lasting \> 3 months
* Back pain that is rated at least 3 on a numeric pain rating scale that ranges from 0 to 10 (0-no pain, 10 worst pain imaginable).
* English language fluency

Exclusion Criteria:

* BMI \> 40
* Inability to provide informed consent
* Recent diagnosis of abdominal aneurism
* Recent diagnosis of metastatic cancer
* Recent diagnosis of discitis
* Recent diagnosis of disk disease
* Recent diagnosis of spinal stenosis
* Recent diagnosis of spondylolisthesis
* Recent diagnosis of infectious cause of back pain
* Recent diagnosis of fracture of vertebra
* Recent diagnosis of Fibromyalgia
* Recent diagnosis of rheumatoid arthritis
* Recent diagnosis of ankylosing spondylitis
* Recent diagnosis of paralysis
* Pregnancy
* Prior or planned back surgery
* Blindness or severe vision problems
* Deafness or severe hearing problems
* Bipolar or manic depression and not taking medication
* Major depression
* Psychoses (major)
* a substance abuse condition
* Dementia
* Unable to get up and down from the floor
* Involvement in a lawsuit related to back pain
* Lack of transportation
* Other disabling chronic conditions (e.g., disabling heart or lung disease, diabetic neuropathy, receiving treatment for hepatitis)
* Currently (within the past 3 months) using yoga classes for more than 15 minutes per week
* Inability to be contacted by phone or email
* no computer access
* schedule does not allow for participation in classes/home practice
* planning to move out of town or take a long vacation during the period of the study
Cracking the Code of Crying Babies: How Familiarity Changes the Interpretation of Cries

Understanding babies' signals is essential to meet their needs. Recent works suggest that crying provides useful information, not only allowing parents to recognize their baby among others (static information), but also to distinguish between mild discomfort and pain cries (dynamic information). The perception of this information by adults involves a "parental" brain network including brain areas involved in empathy, attention, emotional regulation, motor as well as regions of the limbic system or associated with the reward network.

This network is involved when listening to cries of familiar babies, or pain cries. How do we become specialist of a baby's cries? To date, no functional imaging study has examined the specific brain activations when listening to the cries of a familiar baby in different situations, particularly painful ones.

Eligibility Criteria:
Inclusion Criteria

For all volunteers:

* Affiliated or entitled to a social security plan
* Right-handed by the Edinburgh laterality test
* Having given free, informed and written consent to participate in the study
* Having given their consent for the communication of the MRI results to their attending physician

Group with parental experience caring for infants :

* Men or women between 18 and 50 years old
* Parent of a child under 2 years old

Group with professional experience in caring for infants

* Women between 18 and 50 years old
* Without dependent children under 2 years of age
* People in daily contact with infants in the professional circle (e.g. nurses, pediatricians, midwives, maternity nurses, etc)

Exclusion Criteria

* Pregnant women, parturient, nursing mothers or parents
* Persons deprived of liberty, hospitalized without consent, hospitalized for purposes other than research
* Minors
* Adults under legal protection (guardianship) or unable to express their consent
* Subjects with contraindications to the MRI examination: use of a pacemaker or an insulin pump, wearing a metallic prothesis, an intracerebral clip or a piercing, claustrophobia,
* Taking medication for less than 12 hours,
* Neurological, psychiatric or auditory history or deficits.
* Anxiety and/or depressive disorders
Pituitary Adenoma and Serum Lipid

Pituitary adenomas are usually benign monoclonal neoplasms caused by a mixture of pituicyte alterations together with a changed endocrine and paracrine regulatory milieu. Thus, it can cause serious health problems such as abnormal target organ function, pain, disability and even death. In clinical practice, we found many patients with pituitary adenomas are usually accompanied by hyperlipidemia, which is the main cause of cardiovascular diseases. However, it has been unclear if there is an association between pituitary adenomas and serum lipid profile. In the present study, we aim to focus on the patients with pituitary adenomas and their lipid profile before and after operation including first occurrence and recurrence.


Eligibility Criteria:
Inclusion Criteria:

1. Patients diagnosed with pituitary adenomas
2. All adenomas were resected by transsphenoidal surgery and identified by histological diagnoses.

Exclusion Criteria:

1. Missing vital data, such as age, gender, serum lipid profile, pathology reports;
2. Complications or conditions that affect pituitary status and lipid metabolism, such as pregnancy, malignant adenomas or severe hepatic or renal dysfunction and
3. Use of any medication that affects the pituitary or lipid metabolism, including statins, fibrates, thyroid hormones, anti-thyroid drugs, iodine, amiodarone, alemtuzumab, lithium, tyrosine kinase inhibitors, interferon, estrogens, androgens,glucocorticoids, nonsteroidal anti-inflammatory drugs, antiepileptic drugs, rifampicin, furosemide, heparin or β-adrenoceptor blockers in the past 3 months.
Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors

This study is a phase 1B/2 open-label, study to determine safety and preliminary efficacy of Q702 in combination with pembrolizumab in study subjects with advanced esophageal, gastric/GEJ, hepatocellular, and cervical cancers.


Eligibility Criteria:
Inclusion Criteria:

* The participant (or legally acceptable representative if applicable) provides written informed consent for the trial.
* Subjects with histologically or cytologically confirmed advanced or metastatic esophageal, gastric/GEJ, hepatocellular and cervical cancers who have progressed on treatment with an anti-PD1 or anti PD-L1 monoclonal antibody (mAb) administered either as monotherapy, or in combination with other therapies
* Have measurable disease per RECIST v 1.1. as assessed by local site investigator/radiology
* Have an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
* Life expectancy of at least 3 months

Exclusion Criteria:

* A WOCBP who has a positive urine pregnancy test (within 72 hours) prior to treatment or breast-feeding women
* Concomitant use of strong inhibitors and inducers of CYP1A2, 2J2, 2C19, 2D6, and 3A4/5 within the timeline duration of five half-lives prior to starting study drug and throughout the trial
* Concomitant use of sensitive substrates of CYP2C9, 2C19, and 3A4 within the timeline duration of five half-lives prior to starting study drug and throughout the trial
* Has received prior radiotherapy within 2 weeks of start of study treatment or have had a history of radiation pneumonitis
* Has had an allogeneic tissue/solid organ transplant
Clinical Study to Assess the Efficacy of Professional Tooth Whitening Maintenance System

Clinical study to assess the efficacy of professional tooth whitening maintenance system of a Colgate toothpaste containing 5% Hydrogen Peroxide with a stain-fighter mouthwash as compared to only the stainfighter mouthwash and a negative control toothpaste


Eligibility Criteria:
Inclusion Criteria:

* permanent natural teeth (6-11) (22-27)
* composite lobene =\>1
* Signed Informed Consent Form
* Male and female subjects aged 18-70 years, inclusive
* Good general health and good oral health based on the opinion of the study investigator
* All maxillary anterior teeth (teeth #6 through #11) must be present;\& mandibular anterior ( Teeth #22 through 27) must be present
* Availability for the duration of the study
* Minimum average Vita Extended Bleachedguide 3D-Master shade score of 17 ≥ or darker
* A minimum mean of 1.5 ≥ determined by the Interproximal Modified Lobene (IML) Stain Index
* Demonstrate a tendency to form stain in anterior teeth/ Have high staining habits ( coffee/ wine/ tea drinker)

Exclusion Criteria:

* allergies
* Presence of orthodontic appliances or any anterior tooth with a prosthetic crown or veneer
* Restorations on the tooth to be scored which may interfere with scoring procedures
* Obvious signs of periodontal disease, rampant caries, or any condition that the dental examiner considers exclusionary from the study
* Five or more carious lesions requiring immediate care
* Concurrent participation in another clinical study
* Self-reported pregnant and/or lactating women
* History of allergies to tooth whitening products, hydrogen peroxide, personal care consumer products, or their ingredients
* Have dentinal sensitivity
* Taking medication within a year which could alters natural tooth color or appearance,
* Have used Professional Whitening product within a year or had a dental prophylaxis ( professional dental cleaning) within 30 days prior to the start of the study
Survey Assessing the Level of Knowledge of Postoperative Delirium in Poland.

Postoperative Delirium (POD) is one of the most common complications occurring after surgery with an incidence ranging from 4 to 53%. It may lead to increased postoperative morbidity and mortality, with loss of independence and cognitive dysfunction in certain groups of patients. Aiming to reduce the incidence of POD and improve the outcome of patients diagnosed with POD, it is necessary to raise awareness regarding POD. The most important issue are: identification of risk factors, improved monitoring, necessary prevention and adequate treatment. The Polish Society of Anaesthesiology and Intensive Therapy (PTAiIT) has made an attempt to improve the situation in Poland by testing the implementation of official POD guidelines published by the European Society of Anesthesiology in year 2017. While the guidelines provide recommendations for daily practice it is necessary to identify the degree of their implementation in each country. Therefore survey has been prepared regarding postoperative delirium in Poland. This Survey has been submitted to the Bioethical Committee of the Pomeranian Medical University in Szczecin (Poland) and received a waiver due to the non-interventional, observational character of the study (decision no. KB-0012/06/01/2020/Z).


Eligibility Criteria:
Inclusion Criteria:

* Specialists and residents working in the field of anesthesiology and intensive therapy, anesthesiology nurses who respond to an invitation to an on-line survey of the Polish Society of Anesthesiology and Intensive Therapy (PTAiIT)

Exclusion Criteria:

* None
Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor Thrombosis

This is a single-center, single-arm, open-label study that includes patients meeting the inclusion criteria (liver-GTV volume \< 700ml or estimated liver-GTV V5 \< 300ml) with hepatocellular carcinoma with diffuse tumor thrombosis involving both left and right lobes. All lesions receive moderate-dose hypofractionated intensity-modulated radiotherapy, with a gross tumor dose of 25Gy/5f, and a maximum dose of 35Gy/5f at the tumor center. One week before or during the radiotherapy, patients receive concurrent Tislelizumab at a dose of 200mg. Subsequently, Tislelizumab is administered intravenously every 3 weeks. Follow-up examinations are conducted 1-3 months post-radiotherapy. Lenvatinib 4mg may be used for maintenance therapy with Tislelizumab if there are no contraindications. Maintenance therapy is continued until disease progression or intolerance. The primary endpoint is median overall survival (mOS), and secondary endpoints include objective response rate (ORR), progression-free survival (PFS), and toxicity.


Eligibility Criteria:
Inclusion Criteria:

1. Confirmed clinically or histopathologically as hepatocellular carcinoma, concurrently with portal vein thrombosis or hepatic vein thrombosis;
2. Age 18-90 years;
3. Liver-GTV volume\<700ml or the estimated volume of Liver-GTV receiving less than 5 Gy of irradiation\<300ml but the average dose of Liver-GTV needs to be \<18Gy;
4. Allowed previous treatment including TACE, RFA, surgery, chemotherapy, targeted therapy, etc., but not including ICIs such as anti-PD-1, anti-PD-L1, or anti-PD-L2 therapies;
5. ECOG performance status 0-2, expected survival greater than 1 month;
6. Allowing patients with distant metastases;
7. Child-Pugh A5, A6, B7 and B8;
8. ALT within 2.5 times the normal upper limit; AST within 2.5 times the normal upper limit; TBIL \<60umol/L.
9. No significant abnormalities in the electrocardiogram, no apparent heart failure, and no contraindications for anti-PD-1 treatment;
10. CRE, BUN within 2.5 times the normal upper limit;
11. Hb ≥ 50g/L, ANC ≥ 0.5 × 10\^9 /L, PLT ≥ 30 × 10\^9 /L; patients with a history of gastrointestinal bleeding must be controlled for more than 2 weeks before enrollment with Hb ≥ 60g/L and a significant rising trend;
12. Patients voluntarily participate in this clinical trial and sign an informed consent form.

Exclusion Criteria:

1. Currently participating in other clinical trials;
2. Previously received abdominal radiotherapy or liver transplantation;
3. Individuals with severe chronic disease conditions affecting vital organs such as the heart, kidneys, or liver;
4. Severe ascites with noticeable symptoms, anticipated to be unrelieved after treatment.
5. Suspected or confirmed drug addiction, medicine abuse,or alcoholism
6. Pregnant or lactating women;
7. Severe mental or neurological disorders
8. Presence of other life-threatening malignancy within the last 3 years before the start of the study (excluding superficial skin cancer, localized low-grade malignant tumor and in situ carcinoma).
Immunogenicity and Safety Study of Booster Dose of GSK Biologicals' IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib™) Vaccine

The purpose of this booster study is to evaluate the immune persistence in healthy Chinese subjects primed in study NCT01086423 with GSK Biologicals' Infanrix-IPV+Hib™ (DTPa-IPV/Hib) vaccine. The study will also evaluate the safety and immune response of these subjects to a booster dose of Infanrix-Hib™ (DTPa/Hib) and Poliorix™ (IPV) vaccine.

This protocol posting deals with objectives \& outcome measures of the booster phase. The objectives \& outcome measures of the primary phase are presented in a separate protocol posting (NCT number = NCT01086423).


Eligibility Criteria:
Inclusion Criteria:

* A male or female child between, and including, 18 and 24 months of age at the time of the booster vaccination.
* Subjects who completed the full three-dose primary vaccination course in study NCT01086423.
* Subjects who the investigator believes that their parent(s)/ Legally Acceptable Representative(s) LAR(s) can and will comply with the requirements of the protocol
* Written informed consent obtained from the parent(s)/LAR(s) of the subject.
* Healthy subjects as established by medical history and clinical examination before entering into the study.

Exclusion Criteria:

* Child in care
* Use of any investigational or non-registered product other than the study vaccine(s) within 30 days preceding the booster dose of the study vaccine, or planned use during the study period.
* Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the booster dose.
* Administration of a vaccine not foreseen by the study protocol within 30 days prior to the booster vaccination, or planned administration during the study period.
* Participation in another clinical study within three months prior to enrolment in the present booster study or at any time during the present booster study, in which the subject has been or will be exposed to an investigational or a non-investigational product.
* Evidence of previous diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b, vaccination or disease since the conclusion visit of primary study NCT01086423.
* Serious chronic illness.
* Administration of immunoglobulins and/or any blood products within the 90 days preceding the booster dose of study vaccine or planned administration during the study period.
* Occurrence of any of the following adverse events after a previous administration of a DTP vaccine.
* Encephalopathy
* Temperature of ≥ 40.0°C (axillary temperature) within 48 hours of vaccination, not due to another identifiable cause.
* Collapse or shock-like state within 48 hours of vaccination.
* Persistent, inconsolable crying occurring within 48 hours of vaccination and lasting ≥ 3 hours.
* Seizures with or without fever occurring within 3 days of vaccination.

The following condition is temporary or self-limiting, and a subject may be vaccinated once the condition has resolved if no other exclusion criteria is met:

* Acute disease and/or fever at the time of enrolment.